# openai-moderna-chatgpt-enterprise-case-study-2024-04-19

## Veille

OpenAI's official case study on the ChatGPT Enterprise deployment at Moderna: 750 GPTs in 2 months, 100% legal adoption, the Dose ID GPT for clinical trials, Stéphane Bancel's "100,000 employees" quote, an organizational transformation framework (mChat, Generative AI Champions, an internal forum with 2,000 participants).

## Titre Article

Accelerating the development of life-saving treatments — Moderna case study

## Date

2024-04-19

## URL

https://openai.com/index/moderna/

## Keywords

Moderna, OpenAI, ChatGPT Enterprise, custom GPTs, Dose ID, mChat, enterprise AI adoption, organizational transformation, Generative AI Champions, biopharmaceutical, mRNA, Stéphane Bancel, Brad Miller, Brice Challamel, change management, thousand employees vs 100,000, legal team, Contract Companion, Policy Bot, OpenAI partnership, RSV, vaccine

## Authors

OpenAI (étude de cas officielle, citations Stéphane Bancel, Brad Miller, Brice Challamel, Shannon Klinger, Kate Cronin, Meklit Workneh)

## Ton

**Profile**: Corporate customer success story produced by OpenAI, marketing-business register with a heavy weighting of executive quotes. Third-person narration, epic overtones around the mission ("save more lives"), systematic emphasis on the OpenAI–Moderna partnership as a strategic alliance. Target audience: C-level decision-makers at large enterprises evaluating ChatGPT Enterprise adoption, HR and IT teams leading AI transformation, business media.

**Style**: Classic five-act case study structure (Moderna's mission → adoption foundation → the ChatGPT Enterprise decision → the Dose ID example → business impact). Each section anchored by a strong quote from an executive. Vivid metaphors used by Moderna and reproduced verbatim: "we were never here to fill a bucket, but to light a fire" (Challamel), "everyone with a voice and nobody left behind" (Miller), "a team of a few thousand can perform like a team of 100,000" (Bancel). Tone is optimistic, transformative, without contradiction or nuance — this is a promotional document. The document's strength lies in its precise figures (750 GPTs in 2 months, 40% of weekly users creating GPTs, 120 conversations per user per week, 100% legal adoption, 80% for mChat, 2,000 forum participants) that make it highly citable. The document positions itself as the **founding piece of the Moderna AI-first narrative** in the 2024-2025 business press.

## Pense-betes

- Bancel's iconic quote: *"If we had to do it the old biopharmaceutical ways, we might need a hundred thousand people today. We really believe we can maximize our impact on patients with a few thousand people, using technology and AI to scale the company."* — this line has circulated across the press since April 2024.
- Moderna's explicit objective: 100% GenAI adoption and proficiency within 6 months for every employee with digital access.
- Three change management pillars: individual (training + AI learning companions), collective (prompt contests → cohort of 100 Generative AI Champions + weekly internal forum with 2,000 participants), structural (CEO and executive committee involved via town halls and incentives).
- Brice Challamel = Head of AI Products and Platforms (key figure in the rollout, heir to a scientific approach: "we research everything"). Methodical comparison of mChat vs Copilot vs ChatGPT Enterprise → ChatGPT Enterprise's NPS "through the roof."
- Brad Miller = CIO. Cites the anti-hype statistic: *"90% of companies want to do GenAI, but only 10% of them are successful, and the reason they fail is because they haven't built the mechanisms of actually transforming the workforce."*
- mChat = internal chatbot on the OpenAI API launched in early 2023, adopted by 80%+ of employees. Serves as the foundation for ChatGPT Enterprise adoption.
- Key figures two months post-ChatGPT Enterprise: **750 GPTs**, **40% of weekly users create GPTs**, **an average of 120 conversations per user per week**.
- **Dose ID GPT**: clinical data analysis assistant for vaccine dose selection. Generates rationale, references, charts. *"Optimizing the vaccine profile prior to further development in late-stage clinical trials."* A pilot, not a critical system.
- **100% ChatGPT Enterprise adoption in the legal department** (Shannon Klinger, Chief Legal Officer). Contract Companion + Policy Bot. Strong signal on AI usage in what is traditionally among the most cautious functions.
- Brand team: GPTs used to prepare earnings-call slides and translate biotech jargon for investor communications.
- OpenAI-Moderna partnership since early 2023, ChatGPT Enterprise deployed during 2024.
- This is the **founding document** of the Moderna AI-first narrative, later picked up by Fortune, WSJ, Forbes, UNLEASH, and used to justify Tracey Franklin's HR+IT merger a year later.

## RésuméDe400mots

In April 2024, OpenAI published an official case study on the ChatGPT Enterprise deployment at Moderna, the mRNA biotech that has been an OpenAI partner since early 2023. The document positions Moderna as a textbook case of GenAI adoption at scale, with an explicit objective: 100% adoption and proficiency within six months for every employee with digital access.

The foundation was laid in 2023 with mChat, an internal chatbot built on the OpenAI API, adopted by more than 80% of employees. This base allowed Moderna to methodically compare mChat, Copilot, and ChatGPT Enterprise — overseen by Brice Challamel, Head of AI Products and Platforms. Verdict: ChatGPT Enterprise's NPS was *"through the roof."* Decision made to double down on the OpenAI solution.

The two-month results are remarkable: 750 custom GPTs created, 40% of weekly users creating their own, an average of 120 conversations per user per week. The legal department shows **100% adoption** — an unusual outcome for a traditionally cautious function. Signature tools: Contract Companion (contract summaries) and Policy Bot (answers on internal policies).

The flagship pilot is **Dose ID**, a clinical data analysis GPT for vaccine dose selection. It automates the analysis, applies standard criteria, and provides rationales, references, and visualizations. It remains a human decision-support assistant, not a critical system. The brand team also uses GPTs to prepare earnings-call slides and translate biotech jargon for investors.

The success rests on a three-pronged change management framework: **individual** (in-person training, online training, AI learning companions — *"using AI to teach AI was key to our success"*), **collective** (prompt contests identifying 100 power users organized into Generative AI Champions, a weekly internal forum with 2,000 participants, office hours by business line), **structural** (CEO and executive committee engagement via town halls, incentive programs). Brad Miller, CIO, cites the pivotal statistic: *"90% of companies want to do GenAI, but only 10% of them are successful, and the reason they fail is because they haven't built the mechanisms of actually transforming the workforce."*

The document closes with Stéphane Bancel's quote, which has since become iconic: *"If we had to do it the old biopharmaceutical ways, we might need a hundred thousand people today. We really believe we can maximize our impact on patients with a few thousand people, using technology and AI to scale the company."* This line is what turned the Moderna anecdote into an industry signal and fed the narrative of organizational transformation around AI — a narrative that Tracey Franklin (Chief People and Digital Technology Officer) would extend in 2025 with the HR+IT merger.

## GrapheDeConnaissance

- Moderna —collabore_avec→ OpenAI (ORGANISATION, 0.98)
- Moderna —utilise→ ChatGPT Enterprise (TECHNOLOGIE, 0.98)
- Stéphane Bancel —dirige→ Moderna (ORGANISATION, 0.98)
- Stéphane Bancel —affirme_que→ Moderna peut faire le travail de 100 000 employés avec quelques milliers (AFFIRMATION, 0.98)
- Brad Miller —travaille_chez→ Moderna (ORGANISATION, 0.97)
- Brad Miller —affirme_que→ 90% des entreprises veulent la GenAI mais seulement 10% réussissent (AFFIRMATION, 0.95)
- Brice Challamel —dirige→ AI Products and Platforms (ORGANISATION, 0.97)
- Moderna —a_créé→ Dose ID (TECHNOLOGIE, 0.95)
- Moderna —a_créé→ mChat (TECHNOLOGIE, 0.95)
- Dose ID —est_basé_sur→ ChatGPT Enterprise (TECHNOLOGIE, 0.95)
- mChat —est_basé_sur→ OpenAI API (TECHNOLOGIE, 0.95)
- équipe juridique —mesure→ 100% d'adoption ChatGPT Enterprise (MESURE, 0.97)
- Generative AI Champions —est_basé_sur→ top 100 power users IA (CONCEPT, 0.92)
- change management —utilise→ initiatives individuelles, collectives, structurelles (CONCEPT, 0.95)
- Moderna —mesure→ 750 GPTs créés en 2 mois (MESURE, 0.97)
- Shannon Klinger —travaille_chez→ Moderna (ORGANISATION, 0.97)
- Kate Cronin —travaille_chez→ Moderna (ORGANISATION, 0.95)

---
Canonical: https://www.thekb.eu/en/fiches/openai-moderna-chatgpt-enterprise-case-study-2024-04-19/